Noxopharm Limited (ASX:NOX)

Australia flag Australia · Delayed Price · Currency is AUD
0.0890
+0.0040 (4.71%)
Jul 14, 2026, 1:10 PM AEST
Market Cap27.34M +24.8%
Revenue (ttm)3.40M +44.8%
Net Income-5.49M
EPS-0.02
Shares Out 307.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,000
Open0.0890
Previous Close0.0850
Day's Range0.0890 - 0.0890
52-Week Range0.0460 - 0.1350
Beta0.00
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About Noxopharm

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company als... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol NOX
Full Company Profile

Financial Performance

In fiscal year 2025, Noxopharm's revenue was 2.82 million, an increase of 17.52% compared to the previous year's 2.40 million. Losses were -4.88 million, 36.5% more than in 2024.

Financial Statements